Interactions of the Immune System with Skin and Bone Tissue in Psoriatic Arthritis: A Comprehensive Review

Overview

Journal Clin Rev Allergy Immunol

Specialty Allergy & Immunology

Date 2016 Jan 19

PMID 26780035

Citations 16

Authors

Andrea Sukhov

Iannis E Adamopoulos

Emanual Maverakis

Affiliations

Soon will be listed here.

Abstract

Cutaneous psoriasis (e.g., psoriasis vulgaris (PsV)) and psoriatic arthritis (PsA) are complex heterogeneous diseases thought to have similar pathophysiology. The soluble and cellular mediators of these closely related diseases are being elucidated through genetic approaches such as genome-wide association studies (GWAS), as well as animal and molecular models. Novel therapeutics targeting these mediators (IL-12, IL-23, IL-17, IL-17 receptor, TNF) are effective in treating both the skin and joint manifestations of psoriasis, reaffirming the shared pathophysiology of PsV and PsA. However, the molecular and cellular interactions between skin and joint disease have not been well characterized. Clearly, PsV and PsA are highly variable in terms of their clinical manifestations, and this heterogeneity can partially be explained by differences in HLA-associations (HLA-Cw*0602 versus HLA-B*27, for example). In addition, there are numerous other genetic susceptibility loci (LCE3, CARD14, NOS2, NFKBIA, PSMA6, ERAP1, TRAF3IP2, IL12RB2, IL23R, IL12B, TNIP1, TNFAIP3, TYK2) and geoepidemiologic factors that contribute to the wide variability seen in psoriasis. Herein, we review the complex interplay between the genetic, cellular, ethnic, and geographic mediators of psoriasis, focusing on the shared mechanisms of PsV and PsA.

Citing Articles

Prevalence of psoriatic arthritis in Italy: insights from the multicentric MAPSI study.

Serban T, Tramontano G, Pendolino M, Roccatello D, Epis O, Iannone F Front Med (Lausanne). 2025; 11:1484988.

PMID: 39876867 PMC: 11773365. DOI: 10.3389/fmed.2024.1484988.

Real-world evaluation of persistence, effectiveness and usage patterns of tofacitinib in treatment of psoriatic arthritis in Australia.

Littlejohn G, Leadbetter J, Butcher B, Feletar M, OSullivan C, Smith T Clin Rheumatol. 2024; 43(5):1579-1589.

PMID: 38459357 PMC: 11018696. DOI: 10.1007/s10067-024-06930-7.

Real-world effectiveness and persistence of secukinumab in the treatment of patients with psoriatic arthritis.

Alegre-Sancho J, Nunez-Monje V, Campos-Fernandez C, Balaguer-Trull I, Robustillo-Villarino M, Aguilar-Zamora M Front Med (Lausanne). 2023; 10:1294247.

PMID: 38053615 PMC: 10694458. DOI: 10.3389/fmed.2023.1294247.

Comprehensive analysis of mitochondrial DNA variants, mitochondrial DNA copy number and oxidative damage in psoriatic arthritis.

Alwehaidah M, Alsabbagh M, Al-Kafaji G Biomed Rep. 2023; 19(5):85.

PMID: 37881602 PMC: 10594069. DOI: 10.3892/br.2023.1667.

GATA2-Mediated Transcriptional Activation of Notch3 Promotes Pancreatic Cancer Liver Metastasis.

Lin H, Hu P, Zhang H, Deng Y, Yang Z, Zhang L Mol Cells. 2022; 45(5):329-342.

PMID: 35534193 PMC: 9095506. DOI: 10.14348/molcells.2022.2176.

References

Karin M . How NF-kappaB is activated: the role of the IkappaB kinase (IKK) complex. Oncogene. 1999; 18(49):6867-74. DOI: 10.1038/sj.onc.1203219. View

Gudjonsson J, Karason A, Antonsdottir A, Runarsdottir E, Hauksson V, Upmanyu R . Psoriasis patients who are homozygous for the HLA-Cw*0602 allele have a 2.5-fold increased risk of developing psoriasis compared with Cw6 heterozygotes. Br J Dermatol. 2003; 148(2):233-5. DOI: 10.1046/j.1365-2133.2003.05115.x. View

Alamanos Y, Voulgari P, Drosos A . Incidence and prevalence of psoriatic arthritis: a systematic review. J Rheumatol. 2008; 35(7):1354-8. View

Gagliani N, Amezcua Vesely M, Iseppon A, Brockmann L, Xu H, Palm N . Th17 cells transdifferentiate into regulatory T cells during resolution of inflammation. Nature. 2015; 523(7559):221-5. PMC: 4498984. DOI: 10.1038/nature14452. View

Kaipiainen-Seppanen O . Incidence of psoriatic arthritis in Finland. Br J Rheumatol. 1996; 35(12):1289-91. DOI: 10.1093/rheumatology/35.12.1289. View

Gudjonsson J, Johnston A, Sigmundsdottir H, Valdimarsson H . Immunopathogenic mechanisms in psoriasis. Clin Exp Immunol. 2003; 135(1):1-8. PMC: 1808928. DOI: 10.1111/j.1365-2249.2004.02310.x. View

Bettelli E, Carrier Y, Gao W, Korn T, Strom T, Oukka M . Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature. 2006; 441(7090):235-8. DOI: 10.1038/nature04753. View

Boyle W, Simonet W, Lacey D . Osteoclast differentiation and activation. Nature. 2003; 423(6937):337-42. DOI: 10.1038/nature01658. View

Veldhoen M, Hocking R, Atkins C, Locksley R, Stockinger B . TGFbeta in the context of an inflammatory cytokine milieu supports de novo differentiation of IL-17-producing T cells. Immunity. 2006; 24(2):179-89. DOI: 10.1016/j.immuni.2006.01.001. View

10.

Chandran V . The genetics of psoriasis and psoriatic arthritis. Clin Rev Allergy Immunol. 2012; 44(2):149-56. DOI: 10.1007/s12016-012-8303-5. View

11.

Schmidt C . Suicidal thoughts end Amgen's blockbuster aspirations for psoriasis drug. Nat Biotechnol. 2015; 33(9):894-5. DOI: 10.1038/nbt0915-894b. View

12.

Chiraz B, Myriam A, Ines Z, Catherine J, Fatma B, Ilhem C . Deletion of late cornified envelope genes, LCE3C_LCE3B-del, is not associated with psoriatic arthritis in Tunisian patients. Mol Biol Rep. 2014; 41(6):4141-6. DOI: 10.1007/s11033-014-3285-4. View

13.

de Cid R, Riveira-Munoz E, Zeeuwen P, Robarge J, Liao W, Dannhauser E . Deletion of the late cornified envelope LCE3B and LCE3C genes as a susceptibility factor for psoriasis. Nat Genet. 2009; 41(2):211-5. PMC: 3128734. DOI: 10.1038/ng.313. View

14.

Winchester R, Minevich G, Steshenko V, Kirby B, Kane D, Greenberg D . HLA associations reveal genetic heterogeneity in psoriatic arthritis and in the psoriasis phenotype. Arthritis Rheum. 2011; 64(4):1134-44. DOI: 10.1002/art.33415. View

15.

Mrabet D, Laadhar L, Sahli H, Zouari B, Haouet S, Makni S . Synovial fluid and serum levels of IL-17, IL-23, and CCL-20 in rheumatoid arthritis and psoriatic arthritis: a Tunisian cross-sectional study. Rheumatol Int. 2011; 33(1):265-6. DOI: 10.1007/s00296-011-2231-1. View

16.

Adamopoulos I, Chao C, Geissler R, LaFace D, Blumenschein W, Iwakura Y . Interleukin-17A upregulates receptor activator of NF-kappaB on osteoclast precursors. Arthritis Res Ther. 2010; 12(1):R29. PMC: 2875663. DOI: 10.1186/ar2936. View

17.

Geboes L, Dumoutier L, Kelchtermans H, Schurgers E, Mitera T, Renauld J . Proinflammatory role of the Th17 cytokine interleukin-22 in collagen-induced arthritis in C57BL/6 mice. Arthritis Rheum. 2009; 60(2):390-5. DOI: 10.1002/art.24220. View

18.

Hedrick M, Lonsdorf A, Hwang S, Farber J . CCR6 as a possible therapeutic target in psoriasis. Expert Opin Ther Targets. 2010; 14(9):911-22. PMC: 3700805. DOI: 10.1517/14728222.2010.504716. View

19.

Nakae S, Iwakura Y, Suto H, Galli S . Phenotypic differences between Th1 and Th17 cells and negative regulation of Th1 cell differentiation by IL-17. J Leukoc Biol. 2007; 81(5):1258-68. DOI: 10.1189/jlb.1006610. View

20.

Reveille J, Sims A, Danoy P, Evans D, Leo P, Pointon J . Genome-wide association study of ankylosing spondylitis identifies non-MHC susceptibility loci. Nat Genet. 2010; 42(2):123-7. PMC: 3224997. DOI: 10.1038/ng.513. View